Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' ARMAND JP' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 114 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Faivre, S; Raymond, E; Boige, V; Gatineau, M; Buthaut, X; Rixe, O; Bernareggi, A; Camboni, G; Armand, JP
      A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies

      CLINICAL CANCER RESEARCH
    2. Armand, JP
      Interview - Dr Jean Pierre Armand Director of the Federation of Cancer Societies

      EUROPEAN JOURNAL OF CANCER
    3. Shepherd, FA; Fossella, FV; Lynch, T; Armand, JP; Rigas, JR; Kris, MG
      Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials

      SEMINARS IN ONCOLOGY
    4. Ducreux, N; Fizazi, K; Seitz, JF; Becouarn, Y; Armand, JP
      Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer

      BULLETIN DU CANCER
    5. Pivot, X; Raymond, E; Laguerre, B; Degardin, M; Cals, L; Armand, JP; Lefebvre, JL; Gedouin, D; Ripoche, V; Kayitalire, L; Niyikiza, C; Johnson, R; Latz, J; Schneider, M
      Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

      BRITISH JOURNAL OF CANCER
    6. Rougier, P; Adenis, A; Ducreux, M; de Forni, M; Bonneterre, J; Dembak, M; Clouet, P; Lebecq, A; Baille, P; Lefresne-Soulas, F; Blanc, C; Armand, JP
      A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

      EUROPEAN JOURNAL OF CANCER
    7. Fizazi, K; Caliandro, R; Soulie, P; Fandi, A; Daniel, C; Bedin, A; Doubre, H; Viala, J; Rodier, JM; Trandafir, L; Le Chevalier, T; Cvitkovic, E; Armand, JP; Ruffie, P
      Combination raltitrexed (Tomudex (R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

      EUROPEAN JOURNAL OF CANCER
    8. Delord, JP; Raymond, E; Chaouche, M; Ruffie, P; Ducreux, M; Faivre, S; Boige, V; Le Chevalier, T; Rixe, O; Baudin, E; Pautier, P; Rodier, JM; Chouaki, N; Escudier, B; Kayitalire, L; Armand, JP
      A dose-finding study of gemcitabine and vinorelbine in advanced previouslytreated malignancies

      ANNALS OF ONCOLOGY
    9. Andre, F; Raymond, E; Doubre, H; Le Chevalier, T; Armand, JP
      Cell targets of new drugs and results of new chemotherapy schemes in non-small-cell lung cancer.

      REVUE DES MALADIES RESPIRATOIRES
    10. Fandi, A; Bachouchi, M; Azli, N; Taamma, A; Boussen, H; Wibault, P; Eschwege, F; Armand, JP; Simon, J; Cvitkovic, E
      Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type

      JOURNAL OF CLINICAL ONCOLOGY
    11. Boige, V; Raymond, E; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Ducreux, M; Rixe, O; Armand, JP
      Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer

      JOURNAL OF CLINICAL ONCOLOGY
    12. Couteau, C; Risse, ML; Ducreux, M; Lefresne-Soulas, F; Riva, A; Lebecq, A; Ruffie, P; Rougier, P; Lokiec, F; Bruno, R; Armand, JP
      Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    13. Fizazi, K; Ducreux, M; Ruffie, P; Bonnay, M; Daniel, C; Soria, JC; Hill, C; Fandi, A; Poterre, M; Smith, M; Armand, JP
      Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

      JOURNAL OF CLINICAL ONCOLOGY
    14. Armand, JP; Boige, V; Raymond, E; Fizazi, K; Faivre, S; Ducreux, M
      Oxaliplatin in colorectal cancer: An overview

      SEMINARS IN ONCOLOGY
    15. Raymond, E; Faivre, S; Armand, JP
      Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

      DRUGS
    16. Armand, JP
      The Bezwoda scandal

      BULLETIN DU CANCER
    17. Meric, JB; Faivre, S; Monnerat, C; Vago, NA; Le Chevalier, T; Armand, JP; Raymond, E
      ZD 1839 "Iressa"

      BULLETIN DU CANCER
    18. Hasbini, A; Raymond, E; Cvitkovic, E; Eschwege, F; Armand, JP
      Carcinomas of the nasopharynx

      BULLETIN DU CANCER
    19. Soria, JC; Gauthier, LR; Raymond, E; Granotier, C; Morat, L; Armand, JP; Boussin, FD; Sabatier, L
      Molecular detection of telomerase-positive circulating epithelial cells inmetastatic breast cancer patients

      CLINICAL CANCER RESEARCH
    20. Armand, JP; Seymour, L; Evans, TRJ
      Raltitrexed (Tomudex (TM)) in combination with platinum-based agents and/or anthracyclines: Preliminary results of phase I clinical trials

      EUROPEAN JOURNAL OF CANCER
    21. Armand, JP; Cunningham, D; van Cutsem, E; Misset, JL; Kohne, CH
      Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies

      ANTI-CANCER DRUGS
    22. Hasbini, A; Mahjoubi, R; Fandi, A; Chouaki, N; Taamma, A; Lianes, P; Cortes-Funes, H; Alonso, S; Armand, JP; Cvitkovic, E; Raymond, E
      Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type

      ANNALS OF ONCOLOGY
    23. Ducreux, M; Ychou, M; Seitz, JF; Bonnay, M; Bexon, A; Armand, JP; Mahjoubi, M; Mery-Mignard, D; Rougier, P
      Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer

      JOURNAL OF CLINICAL ONCOLOGY
    24. Taamma, A; Fandi, A; Azli, N; Wibault, P; Chouaki, N; Hasbini, A; Couteau, C; Armand, JP; Cvitkovic, E
      Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin,and cisplatin for patients with locally advanced, metastatic, or recurrentundifferentiated carcinoma of the nasopharyngeal type

      CANCER
    25. Alexandre, J; Raymond, E; Armand, JP
      Rapamycin and CCI-779

      BULLETIN DU CANCER
    26. Couteau, C; Chouaki, N; Leyvraz, S; Oulid-Aissa, D; Lebecq, A; Domenge, C; Groult, V; Bordessoule, S; Janot, F; De Forni, M; Armand, JP
      A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

      BRITISH JOURNAL OF CANCER
    27. MONNET I; BRIENZA S; HUGRET F; VOISIN S; GASTIABURU J; SALTIEL JC; SOULIE P; ARMAND JP; CVITKOVIC E; DECREMOUX H
      PHASE-II STUDY OF OXALIPLATIN IN POOR-PROGNOSIS NONSMALL CELL LUNG-CANCER (NSCLC)

      European journal of cancer
    28. DUCREUX M; ROUGIER P; FANDI A; CLAVEROFABRI MC; VILLING AL; FASSONE F; FANDI L; ZARBA J; ARMAND JP
      EFFECTIVE TREATMENT OF ADVANCED BILIARY-TRACT CARCINOMA USING 5-FLUOROURACIL CONTINUOUS-INFUSION WITH CISPLATIN

      Annals of oncology
    29. OBERHOFF C; NERI B; AMADORI D; PETRY KU; GAMUCCI T; REBMANN U; NOWROUSIAN MR; VOIGTMANN R; MONFARDINI S; ARMAND JP; HERRMANN R; NETTERPINON J; TUBIANAMATHIEU N; ZWIERZINA H
      RECOMBINANT-HUMAN-ERYTHROPOIETIN IN THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA AND PREVENTION OF TRANSFUSION REQUIREMENT ASSOCIATED WITH SOLID TUMORS - A RANDOMIZED, CONTROLLED-STUDY

      Annals of oncology
    30. DEGARDIN M; OLIVEIRA J; GEOFFROIS L; ROLLAND F; ARMAND JP; BASTIT P; CHAUVERGNE J; FARGEOT P; VANGLABBEKE M; LENTZ MA; TRESCA P; BOUDILLET J; FUMOLEAU P; CAPPELAERE P
      AN EORTC-ECSG PHASE-II STUDY OF VINORELBINE IN PATIENTS WITH RECURRENT AND OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK/

      Annals of oncology
    31. PIVOT X; RAYMOND E; GEDOUIN D; DEGARDIN W; ARMAND JP; LAGUERRE B; LEFEBVRE JL; RIPOCHE V; KAYITALIRE L; SCHNEIDER M
      PHASE-II TRIAL OF MTA (LY231514) IN ADVANCED OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

      Annals of oncology
    32. DUCREUX M; FIZAZI K; DANIEL C; RUFFLE P; KABOUCHE A; FANDI A; SMITH M; ARMAND JP
      UPDATED RESULTS OF A PHASE-I TRIAL OF TOMUDEX((R)) (T) IN COMBINATIONWITH OXALIPLATIN (L-OHP) IN ADVANCED SOLID TUMORS - A PROMISING AND ACTIVE COMBINATION

      Annals of oncology
    33. FIZAZI K; BONNAY M; FOURCAULT D; RUFFIE P; COUTURAS O; SMITH M; GOMENI R; FANDI A; ARMAND JP
      PHARMACOKINETIC (PK) OF TOMUDEX((R)) (RALTITREXED) (T) AND OXALIPLATIN (0) COMBINATION - PRELIMINARY-RESULTS OF AN ONGOING PHASE-I STUDY

      Annals of oncology
    34. BOIGE V; RAYMOND E; FABBRO M; PLAZZA J; VASSAL G; RISSE ML; RODIER JM; ARMAND JP
      PHASE-II TRIAL AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) IN PATIENTS WITH GLIOBLASTOMA

      Annals of oncology
    35. WASSERMAN E; MYARA A; LOKIEC F; RIOFRIO M; IMADALOU K; BLEUZEN P; SANTONI J; TRIVIN F; HERAIT P; MAHJOUBI M; ARMAND JP; MISSET JL; CVITKOVIC E
      BILIRUBIN (BIL) AND SN-38 - PHARMACOKINETIC PHARMACODYNAMICS CORRELATION/

      Annals of oncology
    36. RAYMOND E; BOIGE V; GATINEAU M; FRAZER S; LAROCHE C; LABBE S; PAUTIER P; DUCREUX M; ARMAND JP
      PHASE-I AND PHARMACOKINETIC STUDY OF DX-8951F, A NOVEL TOPOISOMERASE-1 INHIBITOR, USING A 30 MINUTE INFUSION EVERY 3 WEEKS

      Annals of oncology
    37. SEITZ JF; DUCREUX M; YCHOU M; BONNAY M; ROUGIER P; MIGNARD D; ARMAND JP
      PHASE I II STUDY OF CPT-II IN COMBINATION WITH LV5FU2 (DE GRAMONT-REGIMEN) EVERY 2 WEEKS FOR THE TREATMENT OF COLORECTAL-CANCER (CRC) AFTER5-FU FAILURE/

      Annals of oncology
    38. FIZAZI K; BAUDIN E; RUFFIE P; DUCREUX M; SORIA JC; LECHEVALIER T; BONNAY M; COUTURAS O; FANDI A; ARMAND JP
      AN ONGOING PHASE-I TRIAL OF TOMUDEX(R) (T) IN COMBINATION WITH OXALIPLATIN (L-OHP) IN ADVANCED SOLID TUMORS - A PROMISING AND ACTIVE COMBINATION

      Annals of oncology
    39. CHAOUCHE M; DELORD JP; RAYMOND E; VAYRE L; DUCREUX M; RUFFLE P; RODIER JM; ARMAND JP
      GEMCITABINE AND VINORELBINE, A PHASE-I STUDY IN PATIENTS WITH ADVANCED MALIGNANCIES

      Annals of oncology
    40. RIXE O; GATINEAU M; BATOUCHE M; RAYMOND E; DOMENGE C; JANOT F; SCHWAAB G; LUBOINSKI B; ARMAND JP
      SEQUENTIAL NEOADJUVANT CHEMOTHERAPY (SC) FOR HEAD AND NECK SQUAMOUS-CELL CARCINOMA (HNSCC)

      Annals of oncology
    41. DECREVOISIER R; BOURHIS J; DOMENGE C; WIBAULT P; KOSCIELNY S; LUSINCHI A; MAMELLE G; JANOT F; JULIERON M; LERIDANT AM; MARANDAS P; ARMAND JP; SCHWAAB G; LUBOINSKI B; ESCHWEGE F
      FULL-DOSE REIRRADIATION FOR UNRESECTABLE HEAD AND NECK-CARCINOMA - EXPERIENCE AT THE GUSTAVE-ROUSSY-INSTITUTE IN A SERIES OF 169 PATIENTS

      Journal of clinical oncology
    42. Armand, JP; Dormont, J; Schwebig, A
      Recommendations for the study of medicine combinations for AIDS and cancertreatment

      THERAPIE
    43. Boige, V; Raymond, E; Armand, JP
      Irinotecan: drug schedule, research of combinations, and phase I experiences

      BULLETIN DU CANCER
    44. Couteau, C; Armand, JP
      Combination with irinotecan in solid tumors except colon carcinoma

      BULLETIN DU CANCER
    45. Pignon, JP; Bourhis, J; Domenge, C; Designe, L; Armand, JP; Luboinski, B
      Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): loco-regional treatment versus same treatment plus chemotherapy

      EUROCANCER 98
    46. RIVORY LP; HAAZ MC; CANAL P; LOKIEC F; ARMAND JP; ROBERT J
      PHARMACOKINETIC INTERRELATIONSHIPS OF IRINOTECAN (CPT-11) AND ITS 3 MAJOR PLASMA METABOLITES IN PATIENTS ENROLLED IN PHASE-I II TRIALS/

      Clinical cancer research
    47. FANDI A; TAAMMA A; AZLI N; BACHOUCHI M; YANES B; ARMAND JP; CVITKOVIC E
      PALLIATIVE TREATMENT WITH LOW-DOSE CONTINUOUS-INFUSION 5-FLUOROURACILIN RECURRENT AND OR METASTATIC UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA TYPE/

      Head & neck
    48. TRANDAFIR L; RUFFIE P; BOREL C; MONNET I; SOULIE P; ADAMS D; CVITKOVIC E; ARMAND JP
      HIGHER DOSES OF ALPHA-INTERFERON DO NOT INCREASE THE ACTIVITY OF THE WEEKLY CISPLATIN-INTERFERON COMBINATION IN ADVANCED MALIGNANT MESOTHELIOMA

      European journal of cancer
    49. ROUGIER P; YCHOU M; SEITZ JF; BONNAY M; MIGNARD D; COUTEAU C; ARMAND JP; DUCREUX M
      PHASE-I II STUDY OF CPT-11 IN COMBINATION WITH LV2FU5 (DE-GRAMONT-REGIMEN) EVERY 2 WEEKS FOR THE TREATMENT OF COLORECTAL-CANCER (CRC) AFTER5FU FAILURE/

      European journal of cancer
    50. DEGARDIN M; BASTIT P; ROLLAND F; ARMAND JP; CHEVALLIER B; VANGLABBEKE M; BOUDILLET J; TRESCA P
      PHASE-II STUDY OF VINORELBINE (NVB) IN PATIENTS WITH METASTATIC AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)/

      European journal of cancer
    51. CIULEANU TE; CHAHINE A; TODOR N; MONNET I; AZLI N; VOISIN S; RIGGI M; SALTIEL JC; ARMAND JP; RUFFIE P; DECREMOUX H; CVITKOVIC E
      NEOADJUVANT CISPLATIN-VINDESINE VINORELBINE BASED COMBINATION CHEMOTHERAPY (CT) FOR STAGE-III NONSMALL CELL LUNG-CANCER (NSCLC)/

      European journal of cancer
    52. MERROUCHE Y; EXTRA JM; ABIGERGES D; BUGAT R; CATIMEL G; SUC E; MARTY M; HERAIT P; MAHJOUBI M; ARMAND JP
      HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY

      Journal of clinical oncology
    53. ARMAND JP
      NEW ANTICANCER DRUGS IN EUROPE

      Chinese medical journal
    54. ARMAND JP; DOUSSET V; FRANCONI JM; HUOT P; MIEZE S; LACOSTE D; LETENNEUR L; CAILLE JM
      PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATH Y STUDIED BY MAGNETIZATION-TRANSFER IMAGING

      Journal de radiologie
    55. DOUSSET V; ARMAND JP; LACOSTE D; MIEZE S; LETENNEUR L; DARTIGUES JF; CAILLE JM
      MAGNETIZATION-TRANSFER STUDY OF HIV ENCEPHALITIS AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

      American journal of neuroradiology
    56. ARMAND JP; COSTA A; GERAGHTY J; OHIGGINS N; BROE PJ; HOLMBERG L; SLEIJFER DT; DETOEUF J
      CONTINUING MEDICAL-EDUCATION IN ONCOLOGY IN EUROPE

      European journal of cancer
    57. ABIGERGES D; ARMAND JP; CHABOT GG; BRUNO R; BISSERY MC; BAYSSAS M; KLINKALAKL M; CLAVEL M; CATIMEL G
      PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS

      Anti-cancer drugs
    58. ARMAND JP
      THE CLINICAL RATIONALE FOR DEVELOPING DOCETAXEL (TAXOTERE(R))

      Anti-cancer drugs
    59. ARMAND JP; EXTRA YM; CATIMEL G; ABIGERGES D; MARTY M; CLAVEL M
      RATIONALE FOR THE DOSAGE AND SCHEDULE OF CPT-11 (IRINOTECAN) SELECTEDFOR PHASE-II STUDIES, AS DETERMINED BY EUROPEAN PHASE-I STUDIES

      Annals of oncology
    60. CHABOT GG; ARMAND JP; TERRET C; DEFORNI M; ABIGERGES D; WINOGRAD B; IGWEMEZIE L; SCHACTER L; KAUL S; ROPERS J; BONNAY M
      ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY

      Journal of clinical oncology
    61. WIBAULT P; BENSMAINE MEA; DEFORNI M; ARMAND JP; BERNAL ET; GUILLOT T; RECONDO G; DOMENGE C; JANOT F; BOREL C; LUBOINSKI B; ESCHWEGE F; CVITKOVIC E
      INTENSIVE CONCOMITANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED UNRESECTABLE SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A PHASE-II STUDY OFRADIOTHERAPY WITH CISPLATIN AND 7-WEEK CONTINUOUS INFUSIONAL FLUOROURACIL

      Journal of clinical oncology
    62. SOULIE P; RUFFIE P; TRANDAFIR L; MONNET I; TARDIVON A; TERRIER P; CVITKOVIC E; LECHEVALIER T; ARMAND JP
      COMBINED SYSTEMIC CHEMOIMMUNOTHERAPY IN ADVANCED DIFFUSE MALIGNANT MESOTHELIOMA - REPORT OF A PHASE I-II STUDY OF WEEKLY CISPLATIN INTERFERON ALFA-2A

      Journal of clinical oncology
    63. CVITKOVIC E; ESCHWEGE F; RAHAL M; DOSEN; MERSIC Z; KRAJINA Z; ARMAND JP; BOUHRIS J; TUBIANAMATHIEU M; FOUNTZILAS G; KOSMIDIS PA; PRASAD U; GANESAN S; ELGUEDDARI B; BACHOUCHI M; MANSOURI A; OLIVEIRA J; RAPOSO J; WIERZBICKI R; LIANES P; PENA C; ONAT H; ALTUN M; BENHAMOU E; DUCOURTIEUX M; AZLI N; FANDI A; TAAMMA A; BOSQ J; KLIJANIENKO J; SIGAL R; HONG WK; VOKES EE; CLARK JR; LEFLOCH O; BERNIER J
      PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING NEOADJUVANT CHEMOTHERAPY (CISPLATIN, EPIRUBICIN, BLEOMYCIN) PLUS RADIOTHERAPY VS RADIOTHERAPY ALONE IN STAGE-IV (GREATER-THAN-OR-EQUAL-TO-N2, M0) UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA - A POSITIVE EFFECT ON PROGRESSION-FREESURVIVAL

      International journal of radiation oncology, biology, physics
    64. BENSMAINE MEA; GUILLOT T; BERNAL ET; JANOT F; SIGAL R; DOMENGE C; WIBAULT P; ARMAND JP; CVITKOVIC E
      NEOADJUVANT CHEMOTHERAPY WITH CISPLATIN-VINDESINE-5-FLUOSOURACIL AND FOLINIC ACID FOR LOCALLY ADVANCED HEAD AND NECK-CARCINOMA

      American journal of clinical oncology
    65. BENSMAINE MEA; AZLI N; DOMENGE C; ARMAND JP; CVITKOVIC E
      PHASE I-II TRIAL OF RECOMBINANT INTERFERON-ALPHA-2B WITH CISPLATIN AND 5-FLUOROURACIL IN RECURRENT AND OR METASTATIC CARCINOMA OF HEAD AND NECK/

      American journal of clinical oncology
    66. GIRAULT JM; ARMAND JP; DOUSSET V; DAUBE X; SCHOENENBERGER P; CARLIER P; CAILLE JM
      QUID - MARCHIAFAVA-BIGNAMI DISEASE

      Journal de radiologie
    67. ARMAND JP; DOUSSET V; VIAUD B; HUOT P; CHEHAB Z; DOSSANTOS E; BERGE J; CAILLE JM
      AGENESIS OF THE INTERNAL CAROTID-ARTERY A SSOCIATED WITH AN ANEURYSM OF THE ANTERIOR COMMUNICATING ARTERY

      Journal of neuroradiology
    68. ARMAND JP
      CPT-11 - CLINICAL-EXPERIENCE IN PHASE-I STUDIES

      Seminars in oncology
    69. FOGEL S; AHOMADEGBE JC; BARROIS M; LEBIHAN ML; DOUCRASY S; DUVILLARD P; ARMAND JP; RIOU G
      HIGH-INCIDENCE OF P53 MUTATIONS IN HEAD A ND NECK PRIMARY TUMORS AND METASTASES - FREQUENT P53 PROTEIN OVEREXPRESSION IN NORMAL EPITHELIUM

      Bulletin du cancer
    70. COUTEAU C; YAKENDJI K; TERRET C; GONCALVES E; ARMAND JP
      TAXOTER (DOCETAXEL) AND CPT-11 (IRINOTECA N) - THE PHASE-I TRIALS

      Bulletin du cancer
    71. ARMAND JP; DUCREUX M; MAHJOUBI M; ABIGERGES D; BUGAT R; CHABOT G; HERAIT P; DEFORNI M; ROUGIER P
      CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER

      European journal of cancer
    72. ARMAND JP; COUTEAU C
      CHEMOTHERAPY IN HEAD AND NECK-CANCER

      European journal of cancer
    73. RODIER JM; DACOSTA L; TRANDAFIR L; GIROUX B; CIOLOCA C; HAIEMEDER C; BOREL C; ARMAND JP
      PRETREATMENT WITH PROCARBAZINE DOES NOT CIRCUMVENT THE RESISTANCE TO NITROSOUREA IN THE TREATMENT OF RECURRENT ASTROCYTOMA

      European journal of cancer
    74. DUCREUX M; ROUGIER P; FANDI A; FANDI L; FABRI MC; ZARBA J; ARMAND JP
      DEMONSTRATED EFFICIENCY OF 5-FLUOROURACIL (5FU) CONTINUOUS-INFUSION (CI) AND CISPLATIN (P) IN PATIENTS WITH ADVANCED BILIARY-TRACT CARCINOMA

      European journal of cancer
    75. YAKENDJI K; ROUGIER P; DUCREUX M; DUVILLARD P; FABRI MC; LASSER P; ARMAND JP
      EFFICACY OF THE COMBINATION OF ETOPOSIDE (E) AND CISPLATINUM (P) IN THE TREATMENT OF NEUROENDOCRIN DIGESTIVE CARCINOMA (NEC)

      European journal of cancer
    76. LOKIEC F; CANAL P; MATHIEUBOUE A; ARMAND JP; BUGAT R
      CPT-11 METABOLISM IN BLOOD, BILE AND URINE IN CANCER-PATIENTS

      European journal of cancer
    77. TERRET C; GONCALVES E; DACOSTA L; UROSEVIC V; CHOLLET P; MADELMONT J; ARMAND JP
      PHASE-I TRIAL OF A NEW NITROSUREA INA WEEKLY SCHEDULE

      European journal of cancer
    78. ARMAND JP
      OVERVIEW OF CAMPTOTHECINS

      European journal of cancer
    79. HULNE C; DIELENSEGER P; COUTEAU C; ARMAND JP
      EVALUATION OF QUALITY-OF-LIFE (QOL) WITH LATE NAUSEAS AND VOMITING

      European journal of cancer
    80. MARTY M; KLEISBAUER JP; FOURNEL P; VERGNENEGRE A; CARLES P; LORIAKANZA Y; SIMONETTA C; DEBRUIJN KM; LAURAINE P; DIDIER A; CUPISSOL D; BERGERAT JP; PUJAZON MC; HERON JF; DRENO B; TAYTARD A; GUERIN JC; CLAVIER J; ROBINET G; BLANCHON F; BALMES P; MUIR JF; PAILLOTIN D; POIRIER R; BONNETERRE J; MELLONI B; ROCHE H; DEPIERRE A; PLAGNE R; SOUQUET PJ; ARMAND JP; DEFORNI M
      IS NAVOBAN(R) (TROPISETRON) AS EFFECTIVE AS ZOFRAN(R) (ONDANSETRON) IN CISPLATIN-INDUCED EMESIS

      Anti-cancer drugs
    81. ROYER I; ALVINERIE P; ARMAND JP; HO LK; WRIGHT M; MONSARRAT B
      PACLITAXEL METABOLITES IN HUMAN PLASMA AND URINE - IDENTIFICATION OF 6-ALPHA-HYDROXYTAXOL, 7-EPITAXOL AND TAXOL HYDROLYSIS PRODUCTS USING LIQUID-CHROMATOGRAPHY ATMOSPHERIC-PRESSURE CHEMICAL-IONIZATION MASS-SPECTROMETRY

      Rapid communications in mass spectrometry
    82. AHOMADEGBE JC; BARROIS M; FOGEL S; LEBIHAN ML; DOUCRASY S; DUVILLARD P; ARMAND JP; RIOU G
      HIGH-INCIDENCE OF P53 ALTERATIONS (MUTATION, DELETION, OVEREXPRESSION) IN HEAD AND NECK PRIMARY TUMORS AND METASTASES - ABSENCE OF CORRELATION WITH CLINICAL OUTCOME - FREQUENT PROTEIN OVEREXPRESSION IN NORMAL EPITHELIUM AND IN EARLY NONINVASIVE LESIONS

      Oncogene
    83. CHABOT GG; ABIGERGES D; CATIMEL G; CULINE S; DEFORNI R; EXTRA JM; MAHJOUBI H; HERAIT P; ARMAND JP; BUGAT R; CLAVEL M; MARTY ME
      POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS

      Annals of oncology
    84. GONCALVES E; DACOSTA L; ABIGERGES D; ARMAND JP
      A NEW ENKEPHALINASE INHIBITOR AS AN ALTERNATIVE TO LOPERAMIDE IN THE PREVENTION OF DIARRHEA INDUCED BY CPT-11

      Journal of clinical oncology
    85. SCHORNAGEL JH; VERWEIJ J; DEMULDER PHM; COGNETTI F; VERMORKEN JB; CAPPELAERE P; ARMAND JP; WILDIERS J; DEGRAEFF A; CLAVEL M; SAHMOUD T; KIRKPATRICK A; LEFEBVRE JL
      RANDOMIZED PHASE-III TRIAL OF EDATREXATE VERSUS METHOTREXATE IN PATIENTS WITH METASTATIC AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER HEAD AND NECK-CANCER COOPERATIVE GROUP-STUDY/

      Journal of clinical oncology
    86. ABIGERGES D; CHABOT GG; ARMAND JP; HERAIT P; GOUYETTE A; GANDIA D
      PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS

      Journal of clinical oncology
    87. BOURHIS J; FORTIN A; DUPUIS O; DOMENGE C; LUSINCHI A; MARANDAS P; SCHWAAB G; ARMAND JP; LUBOINSKI B; MALAISE E; ESCHWEGE F; WIBAULT P
      VERY ACCELERATED RADIATION-THERAPY - PRELIMINARY-RESULTS IN LOCALLY UNRESECTABLE HEAD AND NECK CARCINOMAS

      International journal of radiation oncology, biology, physics
    88. LOKIEC F; CANAL P; GAY C; CHATELUT E; ARMAND JP; ROCHE H; BUGAT R; GONCALVES E; MATHIEUBOUE A
      PHARMACOKINETICS OF IRINOTECAN AND ITS METABOLITES IN HUMAN BLOOD, BILE, AND URINE

      Cancer chemotherapy and pharmacology
    89. DEFORNI M; CHABOT GG; ARMAND JP; GOUYETTE A; KLINKALAK M; RECONDO G
      PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION

      Cancer chemotherapy and pharmacology
    90. ARMAND JP; DOUSSET V; WINNOCK S; VIAUD B; BERGE J; CAILLE JM
      DIAGNOSIS OF EXTRAPONTINE MYELINOLYSIS PR ECEDING PONTINE MYELINOLYSIS

      Journal de radiologie
    91. DEGARDIN M; ARMAND JP; CHEVALLIER B; CAPPELAERE P; LENTZ MA; DAVID M; ROCHE H
      A CLINICAL SCREENING COOPERATIVE GROUP PHASE-II EVALUATION OF LOBAPLATIN (ASTA D-19466) IN ADVANCED HEAD AND NECK-CANCER

      Investigational new drugs
    92. LEPRONT D; CROZAT T; MARTIN F; DELEVIS PA; ARMAND JP; IRIARTSORHONDO JP; MASSON F
      RUPTURE OF HYPOGASTRIC ARTERY ANEURYSM INTO THE COMMON ILIAC VEIN

      Journal de chirurgie
    93. CHAKRANI F; ARMAND JP; LENOIR G; JU LY; LIANG JP; MAY E; MAY P
      MUTATIONS CLUSTERED IN EXON-5 OF THE P53 GENE IN PRIMARY NASOPHARYNGEAL CARCINOMAS FROM SOUTHEASTERN ASIA

      International journal of cancer
    94. ROUGIER P; DUCREUX M; MAHJOUBI M; PIGNON JP; BELLEFQIH S; OLIVEIRA J; BOGNEL C; LASSER P; YCHOU M; ELIAS D; CVITKOVIC E; ARMAND JP; DROZ JP
      EFFICACY OF COMBINED 5-FLUOROURACIL AND CISPLATINUM IN ADVANCED GASTRIC CARCINOMAS - A PHASE-II TRIAL WITH PROGNOSTIC FACTOR-ANALYSIS

      European journal of cancer
    95. ARMAND JP; ALBERTO P; COSTA A; ESTAPE J; JONES RVH; OVERGAARD J; SHERMAN CD
      EUROPEAN SCHOOL OF ONCOLOGY ADVISORY REPORT TO THE COMMISSION OF THE EUROPEAN COMMUNITIES FOR THE EUROPE AGAINST CANCER PROGRAM - CONTINUING MEDICAL-EDUCATION IN ONCOLOGY WITHIN THE EUROPEAN UNION

      European journal of cancer
    96. GOEDHALS L; JORDAAN JP; KAYE SB; ARMAND JP; VEENHOF CHN; FALKSON G; SOUKOP M; SCHNEIDER M; OBERLING F; BUI BN; ROCHE H; ADENIS L; CATY A; BLIJHAM GH; DEWEWEIRE A; COIFFIER B; SOTTO JJ; VANHEUKELOM LS; TAGNON A; SLEE PHTJ; KROEKS MVAM; RAVEZ P; CUPISSOL D; KEIZER HJ; BRUNNER K; CALVERT AH; YERNAULT JC; LIBERT P; BROHEE D
      A DOSE-FINDING STUDY OF GRANISETRON, A NOVEL ANTIEMETIC, IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN

      Supportive care in cancer
    97. ARMAND JP
      REMEMBERING CLAVEL,MICHEL

      Annals of oncology
    98. TOUSSAINT C; IZZO J; SPIELMANN M; MERLE S; MAYLEVIN F; ARMAND JP; LACOMBE D; TURSZ T; SUNDERLAND M; CHABOT GG; CVITKOVIC E
      PHASE I II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER/

      Journal of clinical oncology
    99. FANDI A; ALTUN M; AZLI N; ARMAND JP; CVITKOVIC E
      NASOPHARYNGEAL CANCER - EPIDEMIOLOGY, STAGING, AND TREATMENT

      Seminars in oncology
    100. BOURHIS J; WILSON G; WIBAULT P; BOSQ J; ARMAND JP; LUBOINSKI B; MALAISE EP; ESCHWEGE F; JANOT F
      RAPID TUMOR-CELL PROLIFERATION AFTER INDUCTION CHEMOTHERAPY IN OROPHARYNGEAL CANCER

      The Laryngoscope


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/10/20 alle ore 02:05:45